You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for bupropion hydrochloride; dextromethorphan hydrobromide and what is the scope of patent protection?

Bupropion hydrochloride; dextromethorphan hydrobromide is the generic ingredient in one branded drug marketed by Axsome and is included in one NDA. There are one hundred and twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bupropion hydrochloride; dextromethorphan hydrobromide has one hundred and ninety-five patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE
International Patents:195
US Patents:120
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 1
DailyMed Link:BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE
Generic Entry Date for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical University of South CarolinaPhase 1

See all BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE clinical trials

Paragraph IV (Patent) Challenges for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
AUVELITY Extended-release Tablet bupropion hydrochloride; dextromethorphan hydrobromide 45 mg/105 mg 215430 1 2022-12-22

US Patents and Regulatory Information for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Axsome AUVELITY bupropion hydrochloride; dextromethorphan hydrobromide TABLET, EXTENDED RELEASE;ORAL 215430-001 Aug 18, 2022 RX Yes Yes 11,207,281 ⤷  Subscribe ⤷  Subscribe
Axsome AUVELITY bupropion hydrochloride; dextromethorphan hydrobromide TABLET, EXTENDED RELEASE;ORAL 215430-001 Aug 18, 2022 RX Yes Yes 10,105,361 ⤷  Subscribe ⤷  Subscribe
Axsome AUVELITY bupropion hydrochloride; dextromethorphan hydrobromide TABLET, EXTENDED RELEASE;ORAL 215430-001 Aug 18, 2022 RX Yes Yes 11,382,874 ⤷  Subscribe ⤷  Subscribe
Axsome AUVELITY bupropion hydrochloride; dextromethorphan hydrobromide TABLET, EXTENDED RELEASE;ORAL 215430-001 Aug 18, 2022 RX Yes Yes 11,541,048 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

Country Patent Number Title Estimated Expiration
European Patent Office 3908270 ⤷  Subscribe
China 113797205 包含安非他酮或相关化合物和右美沙芬的组合物和方法 (COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN) ⤷  Subscribe
China 106163522 包含安非他酮或相关化合物和右美沙芬的组合物和方法 (Compositions and methods comprising bupropion or related compounds and dextromethorphan) ⤷  Subscribe
European Patent Office 4373480 TRAITEMENT DE LA DÉPRESSION (TREATMENT OF DEPRESSION) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2316456 122017000109 Germany ⤷  Subscribe PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 20150326
2316456 17C1058 France ⤷  Subscribe PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456 2017/059 Ireland ⤷  Subscribe PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150326
2316456 CA 2017 00062 Denmark ⤷  Subscribe PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Bupropion Hydrochloride and Dextromethorphan Hydrobromide

Introduction to Bupropion and Dextromethorphan

Bupropion hydrochloride and dextromethorphan hydrobromide, combined in the drug Auvelity, have recently gained significant attention for their therapeutic applications, particularly in treating major depressive disorder (MDD) and other conditions. This article delves into the market dynamics and financial trajectory of this drug combination.

Market Size and Growth

The global dextromethorphan market, which includes the combination of bupropion and dextromethorphan, is projected to experience steady growth. The market is expected to register a Compound Annual Growth Rate (CAGR) of 4.1% to 4.8% over the forecast period from 2023 to 2030[1][3][4].

Current Market Size

As of 2022, the global dextromethorphan market was valued at approximately USD 487.25 million. It is anticipated to reach USD 587.31 million by 2030[3].

Forecasted Growth

The growth is driven by increasing cases of respiratory conditions such as the common cold, flu, bronchitis, and allergies, which heighten the demand for cough suppressants like dextromethorphan. Additionally, the approval of new formulations, such as Auvelity for MDD, further boosts market expansion[1][3].

Key Drivers of Market Growth

Increasing Prevalence of Cough-Related Conditions

The rising prevalence of respiratory conditions is a significant driver. For instance, flu affects around 8.0% of the United States population annually, leading to a high demand for cough medications[1].

Growing Consumer Awareness and Self-Medication

Increased access to healthcare information has led to greater consumer awareness and a shift towards self-medication. This trend is particularly evident in the over-the-counter (OTC) segment, which dominates the dextromethorphan market[3].

Product Launches and Approvals

Recent approvals, such as the FDA approval of Auvelity in August 2022 for treating MDD, are expected to significantly impact market growth. Other ongoing clinical trials, like the study by Axsome Therapeutics for agitation linked with Alzheimer's disease, also indicate potential future growth[1][2].

Regional Market Analysis

North America

North America currently holds the largest market share due to a strong base of healthcare facilities, a high prevalence of respiratory conditions, and a significant presence of major pharmaceutical companies. For example, during the 2022 influenza season, Canada reported 16,126 laboratory-confirmed influenza detections, highlighting the region's demand for dextromethorphan[1].

Asia Pacific

The Asia Pacific region is expected to be the fastest-growing market. This growth is attributed to government initiatives promoting healthcare awareness, an increase in healthcare facilities, and a large population pool with growing demand for quality healthcare[1][3].

Competitive Landscape

The dextromethorphan market is slightly fragmented, with several notable companies operating globally and regionally. Key players include:

  • AstraZeneca
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Ltd.
  • Pfizer
  • Sun Pharmaceutical
  • Axsome Therapeutics

These companies are known for their significant market shares and innovative product launches[1][3][4].

Mechanism of Action and Therapeutic Applications

Dextromethorphan

Dextromethorphan acts as an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist and a sigma-1 receptor agonist. This mechanism is crucial in its antidepressant and cough suppressant effects[2][5].

Bupropion

Bupropion is a norepinephrine and dopamine reuptake inhibitor (NDRI) and a CYP2D6 inhibitor, which enhances the bioavailability and duration of action of dextromethorphan. Together, they provide a synergistic effect in treating MDD[2][5].

Financial Implications

Market Value

The financial trajectory of the dextromethorphan market, including the bupropion and dextromethorphan combination, is positive. The market's projected growth from USD 487.25 million in 2022 to USD 587.31 million by 2030 indicates a robust financial outlook[3].

Cost and Accessibility

The cost of Auvelity, the drug combining bupropion and dextromethorphan, varies based on insurance plans and pharmacies. However, the availability of savings cards and coupons can make the medication more accessible to patients[5].

Challenges and Restraints

Side Effects

Despite the market growth, side effects associated with dextromethorphan drugs are a significant restraint. These side effects can limit the market expansion and necessitate careful monitoring and management[1].

Future Outlook

The future of the bupropion and dextromethorphan market looks promising, driven by increasing demand for effective treatments for MDD and respiratory conditions. Ongoing research and clinical trials are expected to introduce new therapeutic applications, further boosting market growth.

"The launch of dextromethorphan-based drugs is also expected to boost the market expansion. For instance, in September 2021, in India, Sun Pharmaceutical Industries launched a novel formulation in cough management, Chericof 12 (dextromethorphan hydrobromide 30 mg and chlorpheniramine maleate 4 mg)"[1].

Key Takeaways

  • The global dextromethorphan market is expected to grow at a CAGR of 4.1% to 4.8% from 2023 to 2030.
  • The market is driven by increasing cases of respiratory conditions and the launch of new formulations like Auvelity.
  • North America holds the largest market share, while the Asia Pacific region is expected to be the fastest-growing market.
  • Key players include AstraZeneca, Aurobindo Pharma, Glenmark Pharmaceuticals Ltd., Pfizer, and Sun Pharmaceutical.
  • The combination of bupropion and dextromethorphan has a synergistic effect in treating MDD.

FAQs

What is the current market size of the dextromethorphan market?

The global dextromethorphan market was valued at approximately USD 487.25 million in 2022[3].

Who are the major players in the dextromethorphan market?

Major players include AstraZeneca, Aurobindo Pharma, Glenmark Pharmaceuticals Ltd., Pfizer, and Sun Pharmaceutical[1][3][4].

What is the fastest-growing region in the dextromethorphan market?

The Asia Pacific region is expected to be the fastest-growing market during the forecast period[1][3].

What are the key drivers of the dextromethorphan market growth?

Key drivers include the increasing prevalence of cough-related conditions, growing consumer awareness and self-medication, and product launches and approvals[1][3].

What are the potential challenges for the dextromethorphan market?

Side effects associated with dextromethorphan drugs are a significant restraint that could limit market expansion[1].

Sources

  1. Mordor Intelligence: Dextromethorphan Market Size & Share Analysis - Growth Trends.
  2. PubMed: Dextromethorphan/Bupropion: First Approval.
  3. Data Bridge Market Research: Dextromethorphan Market Size, Scope, Growth, Value & Statistics.
  4. GI Intelligence: Dextromethorphan - Market Share Analysis, Industry Trends.
  5. Drugs.com: Bupropion and Dextromethorphan: Uses, Dosage, Side Effects.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.